Looking for 3 fast-growing ASX shares to invest in and beat the S&P/ASX 200 (INDEXASX: XJO) index? Consider these three companies below.

Nanosonics Ltd (ASX: NAN)

Nanosonics manufacturers the Trophon EPR ultrasound probe disinfector and its related consumables. Nanosonics is seen similar to the Gillette model as customers buy the Trophon EPR system (the razor), then buy consumables (blades) which are high margin and recurring.

You can read more about Nanosonics’ impressive half-year results here, along with Andrew Page’s coverage from strawman.com.

CSL Ltd (ASX: CSL)

CSL is Australia’s largest healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Government to Australian investors in 1994 at $2.30 per share. Today, CSL is a global leader in blood plasma vaccines and antivenoms, providing relief for potentially life-threatening medical conditions.

You can see CSL’s half-year results here or get Rask Media’s view of whether it may (or may not) be the right time to buy.

Cochlear Ltd (ASX: COH)

Cochlear is one of the world’s leading medical business. Cochlear designs, manufactures and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant. Graeme Clark invented the first device in 1982, allowing first-user Graham Carrick to hear for the first time for 17 years.

Cochlear is a very impressive business double-digit sales and profit growth, which you can find here.

NEW SMALL CAPS INVESTING REPORT!

After searching through a market with over 2,000 shares, our lead expert investment analyst has narrowed it down to just 2 of his favourite rapid-growth shares in a FREE report to Rask Media readers.

Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 300.

Idea #1 is taking on the world with an online marketplace capable of generating serious free cash flow. This company's addressable opportunity is multiples of its current valuation.

Idea #2 is a technology business with super-sticky revenue and mission critical software. With operations around the globe, this growth stock has many years of potential.

Access the free report by clicking here now. Absolutely no credit card or payment details required.



Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).